• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    1/2/24 12:35:29 PM ET
    $ABBV
    $ALNY
    $CVS
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    CVS CALL TRADE BULLISH 01/05/24 $81.00 $29.7K 617 1.3K
    LLY CALL SWEEP BULLISH 02/16/24 $600.00 $38.3K 1.0K 851
    GILD CALL SWEEP BULLISH 01/12/24 $85.00 $33.6K 3.7K 534
    ABBV CALL SWEEP BEARISH 01/19/24 $155.00 $25.2K 17.5K 505
    MRNA CALL SWEEP BULLISH 02/16/24 $120.00 $34.1K 571 437
    PFE CALL TRADE BULLISH 01/17/25 $20.00 $51.2K 1.8K 112
    ALNY PUT SWEEP BULLISH 04/19/24 $190.00 $82.4K 91 110
    MRK CALL SWEEP BULLISH 03/15/24 $100.00 $40.6K 32 89
    IONS CALL SWEEP BULLISH 01/19/24 $50.00 $43.0K 526 76
    IMGN CALL SWEEP BULLISH 01/19/24 $15.00 $73.0K 6.4K 50

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • For CVS (NYSE:CVS), we notice a call option trade that happens to be bullish, expiring in 3 day(s) on January 5, 2024. This event was a transfer of 350 contract(s) at a $81.00 strike. The total cost received by the writing party (or parties) was $29.7K, with a price of $85.0 per contract. There were 617 open contracts at this strike prior to today, and today 1383 contract(s) were bought and sold.

    • For LLY (NYSE:LLY), we notice a call option sweep that happens to be bullish, expiring in 45 day(s) on February 16, 2024. This event was a transfer of 15 contract(s) at a $600.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $38.3K, with a price of $2557.0 per contract. There were 1073 open contracts at this strike prior to today, and today 851 contract(s) were bought and sold.

    • Regarding GILD (NASDAQ:GILD), we observe a call option sweep with bullish sentiment. It expires in 10 day(s) on January 12, 2024. Parties traded 501 contract(s) at a $85.00 strike. This particular call needed to be split into 30 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $67.0 per contract. There were 3776 open contracts at this strike prior to today, and today 534 contract(s) were bought and sold.

    • Regarding ABBV (NYSE:ABBV), we observe a call option sweep with bearish sentiment. It expires in 17 day(s) on January 19, 2024. Parties traded 50 contract(s) at a $155.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $25.2K, with a price of $505.0 per contract. There were 17585 open contracts at this strike prior to today, and today 505 contract(s) were bought and sold.

    • For MRNA (NASDAQ:MRNA), we notice a call option sweep that happens to be bullish, expiring in 45 day(s) on February 16, 2024. This event was a transfer of 50 contract(s) at a $120.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $34.1K, with a price of $685.0 per contract. There were 571 open contracts at this strike prior to today, and today 437 contract(s) were bought and sold.

    • For PFE (NYSE:PFE), we notice a call option trade that happens to be bullish, expiring in 381 day(s) on January 17, 2025. This event was a transfer of 50 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $51.2K, with a price of $1025.0 per contract. There were 1839 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold.

    • Regarding ALNY (NASDAQ:ALNY), we observe a put option sweep with bullish sentiment. It expires in 108 day(s) on April 19, 2024. Parties traded 38 contract(s) at a $190.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $82.4K, with a price of $2170.0 per contract. There were 91 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold.

    • For MRK (NYSE:MRK), we notice a call option sweep that happens to be bullish, expiring in 73 day(s) on March 15, 2024. This event was a transfer of 28 contract(s) at a $100.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $40.6K, with a price of $1450.0 per contract. There were 32 open contracts at this strike prior to today, and today 89 contract(s) were bought and sold.

    • For IONS (NASDAQ:IONS), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on January 19, 2024. This event was a transfer of 100 contract(s) at a $50.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $43.0K, with a price of $430.0 per contract. There were 526 open contracts at this strike prior to today, and today 76 contract(s) were bought and sold.

    • Regarding IMGN (NASDAQ:IMGN), we observe a call option sweep with bullish sentiment. It expires in 17 day(s) on January 19, 2024. Parties traded 50 contract(s) at a $15.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $73.0K, with a price of $1460.0 per contract. There were 6497 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $ALNY
    $CVS
    $GILD

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Gilead Sciences Inc.
    $GILD
    2/20/2026$155.00Equal Weight
    Barclays
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    AbbVie Inc.
    $ABBV
    2/20/2026$275.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    More analyst ratings

    $ABBV
    $ALNY
    $CVS
    $GILD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALNY
    $CVS
    $GILD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, R&D and CSO Thakkar Roopal was granted 18,137 shares, increasing direct ownership by 43% to 60,413 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:36:48 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan was granted 53,749 shares, increasing direct ownership by 101% to 106,983 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:35:24 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, GC AND SECRETARY Siatis Perry C was granted 33,518 shares, increasing direct ownership by 726% to 38,137 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:35:21 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALNY
    $CVS
    $GILD
    SEC Filings

    View All

    SEC Form S-8 filed by Moderna Inc.

    S-8 - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:03:07 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Moderna Inc.

    10-K - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:02:04 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by AbbVie Inc.

    10-K - AbbVie Inc. (0001551152) (Filer)

    2/20/26 2:38:42 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALNY
    $CVS
    $GILD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $ALNY
    $CVS
    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

    First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trialRegimen offers another option for the potential of time off treatment, marking a meaningful advance in long-term disease managementNORTH CHICAGO, Ill., Feb. 20, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The approval is supported by data from the Phas

    2/20/26 2:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

    Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years  Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's diseaseINDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE:LLY) showed Omvoh (mirikizuma

    2/19/26 12:15:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALNY
    $CVS
    $GILD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Merck with a new price target

    Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00

    2/20/26 8:25:04 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Gilead Sciences with a new price target

    Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00

    2/20/26 8:24:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $ALNY
    $CVS
    $GILD
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par

    12/18/25 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $ALNY
    $CVS
    $GILD
    Financials

    Live finance-specific insights

    View All

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

    – Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – Gilead Sciences, Inc. (NASDAQ:GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities af

    2/17/26 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

    − Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024 – − Attained GAAP and non-GAAP Profitability for Full Year 2025, with Sustainable Growth in Operating Income Expected – − Launched "Alnylam 2030" Strategy Focused on Scaling Alnylam through Durable ATTR Leadership, Long-Term Sustainable Innovation, and Exceptional Financial Results – − Announced 2026 Pipeline Goals, Including 4 Clinical Readouts, 3 Ongoing Pivotal Studies, 3 Phase 2 Study Initiations, and 3+ New IND Filings – − Reiterates Net Product Sales Guidance and Provides Additional 2026 Fin

    2/12/26 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALNY
    $CVS
    $GILD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 8:34:57 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 1:28:29 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples